American Head and Neck Society position statement on the use of <scp>PD</scp> ‐1 inhibitors for treatment of advanced cutaneous squamous cell carcinoma-Reference-Cited by-同舟云学术

American Head and Neck Society position statement on the use of PD ‐1 inhibitors for treatment of advanced cutaneous squamous cell carcinoma

Published:2022-09-30 Issue:1 Volume:45 Page:32-41
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Schmalbach Cecelia E.¹^ORCID,Ow Thomas J.²^ORCID,Choi Karen Y.³,O'Leary Miriam⁴,Lin Alice⁵,Hughley Brian B.⁶,Emerick Kevin S.⁷^ORCID,Moore Brian⁸,Lee Nancy Y.⁹,Zandberg Dan P.¹⁰^ORCID,Wang Steven J.¹¹

Affiliation:

1. Department of Otolaryngology – Head and Neck Surgery Temple University Philadelphia Pennsylvania USA

2. Department of Otorhinolaryngology – Head and Neck Surgery Montefiore Medical Center, Albert Einstein College of Medicine Bronx New York USA

3. Department of Otolaryngology – Head and Neck Surgery Penn State College of Medicine Hershey Pennsylvania USA

4. Department of Otolaryngology – Head and Neck Surgery Tufts University Boston Massachusetts USA

5. Department of Otolaryngology – Head and Neck Surgery Kaiser Permanente Los Angeles California USA

6. University of Florida Health Gainesville Florida USA

7. Department of Otolaryngology – Head and Neck Surgery Massachusetts Eye and Ear Infirmary Boston Massachusetts USA

8. Ochsner Medical Center New Orleans Louisiana USA

9. Memorial Sloan Kettering Cancer Center Head and Neck Radiation Oncology New York City New York USA

10. Division of Hematology/Oncology, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA

11. Department of Otolaryngology – Head and Neck Surgery University of Arizona Tucson Arizona USA

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.27202

Reference52 articles.

1. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

2. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

3. National Comprehensive Cancer Network.Squamous Cell Skin Cancer (Version 1.2022).https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed 5/1/2022.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in the Management of Advanced Nonmelanoma Skin Cancer;Surgical Oncology Clinics of North America;2024-10

2. Successful Treatment of Cutaneous Squamous Cell Cancer with Cemiplimab—A Report of Two Cases Demonstrating the Management of Pseudoprogression and Adverse Events;Journal of Clinical Medicine;2024-07-19

3. Considering Innovative Clinical Care for Organ Transplant Patients With Advanced Cutaneous Head and Neck Malignancies;Otolaryngology–Head and Neck Surgery;2023-09-13

4. Surgery in the Era of Immunotherapy for Advanced Head and Neck Non-melanoma Skin Cancer;Current Oncology Reports;2023-04-03